Intellia Therapeutics
Prix: 12.11Entreprise et modèle économique
Intellia Therapeutics is a biotechnology company focused on developing gene-editing therapies using CRISPR technology. Its core products include NTLA-2001, aimed at treating transthyretin amyloidosis, and NTLA-2002 for treating hereditary angioedema. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. Intellia is positioned as a niche player in the biotech industry.
Profil d’investissement
The investment profile of Intellia Therapeutics is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue generation. The company currently does not offer dividends, and its financial performance indicates a higher risk profile. Investors may consider a medium to long-term horizon to assess the development of its pipeline.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -3.54 Risque
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -34.6% ↓
- Surprise BPA
- 12.0% meilleur que prévu
- Volatilité 20 j
- 5.3% normal
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-11 05:23 | Conserver | Vendre | scenario_deterioration |
| 2026-06-05 02:44 | Vendre | Conserver | Weak fundamentals offset by recent positive momentum. |
| 2026-05-28 02:53 | Conserver | Vendre | Weak fundamentals with recent positive momentum. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-13 10:28 | Bernstein | Objectif relevé | 13 → 17 | 13.99 |
| 2026-05-12 10:42 | Canaccord Genuity | Objectif abaissé | 58 → 49 | 14.42 |
| 2026-04-27 17:56 | Chardan Capital | Objectif relevé | 27 → 30 | 13.03 |
Rien pour le moment